Sheet

Examiner

PTO/SB/08e (05-03) Approved for use through 04/30/2003. OMB 0651-0031 Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Compl te if Known Application Number 10/051,776 Filing Date 01/16/2002 First Named Inventor Edward Pierson Art Unit **Examiner Name** Attorney Docket Number 100507-

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
(A)		^{US-} 5914401 A	06/22/1999	Egle et al.	
m		^{US-} 6552054 B1	4/22/2003	Yasuma et al.	
		US-		·	
		US-			-5∕2∧
		US-	_		, ,,,,,
		US-			Ec, 4, 5,
		US-			Ca. On A
		US-	-		20
		US			(%)
		US-	····		000
		Us-			300
		US			-60
		US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
		US			
•		US-			1.
		US-			

1	1	. FOREIG	N PATENT DOCL	MENTO	
ceminer Cite	Foreign P	stent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,
itials* No.	Country Coo	le 3-Number 4-Kind Code 6 (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
2	EP	0104018 A2	03/28/1984	Fisons PLC.	
SY	EP	0017578	10/15/1980	C M Industries Societe Anonyme Dite	
()	DE	2331138 A	01/10/1974	Fujisawa Pharmaceutical Co. Ltd.	·
					;

EXAMINER: Initial if reference considered, whether not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not "EXAMINER: Initial if reference considered, whether-or not citation is in conformance with MPEP 609. Draw line through cusuon it not in conformance and not considered, Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.usnto.gov or MPEP 901.04. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 2 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sental number of the patent document. 3 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 8 Applicant is to place a check mark feet. Translation is attached.

Date Considered

This collection is information is required by 37-CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fill (and by the public which is a stimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case: "Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patentiand Trademark Office, U.S. Department of Commercia, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT-OF COMMERCE suction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

	C mpl t if Kn wn	(C)
Application Number	10/051,776	15 17 18 18 18 18 18 18 18 18 18 18 18 18 18
Filing Date	01/16/2002	Const
First Named Inventor	Edward Pierson	(C) 300
Art Unit	1614	180
Examiner Name		0/2
Attorney Docket Number	100507-1	The state of the s

Examiner Initials*	Cite No.1					
Sys	/	FRANK KERRIGAN ET AL, "Synthesis of Arylpipers of Bromoarenes with N-tert-butoxycarbonylpiperazine,	uzines via Palladium-Catalysed Aromatic Amination Reactions "Tetrahedron Letters, Volume 39, 1998, p. 2219-2222,	7		
De	. /	Internation Search Report		1		
			: : :	7		
:						
	. :		•	×4:		
· ;				ri 😅		
		: .				
		:	-			
	·			on.		

Olginature	<u> </u>		Considered	1 1 7 1
*EXAMINER: Initial	if reference considered, v	hether or not citation is in conformance	with MPEP 609. Draw line through citat	on if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete including gathering; preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Offices, U.S. Pategit and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

in conformance and not considered. In PTO/SR/Q8 (2-92)



DOCKET NUMBER

Form PTO-1449

Sheet 1 of 1

US APPLICATION NUMBER

10/051,776

100507 - 1 **APPLICANT** · INFORMATION DISCLOSURE CATAGON AstraZeneca AB BY APPLICANT GROUP ART UNIT **FILING DATE** Not Known January 16, 2002 (Use several sheets if necessar TOTAL PRACTICAL TO DOCUMENTS Examiner Class Subclass Filing Date ... Document Date Name Initial Number If Appropriate 3,862,143 January 21, 1975 Klutchko et al. 3,937,837 February 10, 1976 Klutchko et al. February 19, 1980 4,189,498 Kabbe et al. 4,307,020 December 22, 1981 Kabbe et al. 5.171.865 December 15, 1992 Kurono et all FOREIGN PATENT DOCUMENTS **Document Number Public Date** Country Class Subclass <u>Translation</u> WO 9734883 September 25, 1997 **PCT** EP 0000377 January 24, 1979 XX **EPO** WO 9827058 June 25, 1998 PCT WO 9827080 June 25, 1998 PCT WO 9914207 March 25, 1999 PCT WO 9914212 March 25, 1999 PCT WO 9914213 March 25, 1999 PCT WO 0012623 / March 9, 2000 PCT March 8, 2001 WO 01/161127 PCT JP 2001-261657 Sept 26, 2001 JP . The relevant sections have been translated OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Chemistry Letters 1997, Raposo et al. "The Effect of Chromenone Receptors on the Selectivity of the Reaction between Pyrrolidine and 5-Hydroxymethyl-2-(5H)-Furanone", pp 173-174. Journal of Medicinal Chemistry, Clitherow et al, "Evolution of a Novel Series of Antagonists", Volume 37, No 15, pp 2253-2257 DATE CONSIDERED **EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. PTO/SB/08 (2-92) Patent and Trademark Office, U.S. Department of Commerce

	OIPE	
	JUN 2 5 2002 5	
Form PTO-1449	12 2	

Sheet 1 of

LOSURE CITATION 2nd INFORMATON **BY APPLICANT**

(Use several sheets if necessary)

	01100t <u>1-</u> 0	_
DOCKET NUMBER 100507 - 1	US APPLICATION NUMBER 10/051,776	₹
APPLICANT AstraZeneca AB		
FILING DATE January 16, 2002	GROUP ART UNIT	

U.S. PATENT DOCUMENTS

		0.3.	PAILINI DOCUMENTS			
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
O.	5,403,842	April 4, 1995	Leonardi et al.			
SEL	5,605,896	February 25, 1997	Leonardi et al.			
	·5,965,575	October 12, 1999	Peglion et al.			
80	5,968,954	October 19, 1999	Peglion et al.		<u>~</u> ;	i
					:	1

FOREIGN PATENT DOCUMENTS

	Document Number	Public Date	Country	Class	Subclass	Trans	slation
- 6		·			<u> </u>	Yes	No
87	WO 99/05140 /	February 4, 1999	РСТ				
X	WO 00/40554	July 13, 2000	РСТ		-		
200	WO 01/16127	March 8, 2001	PCT			xx	
1	÷						
	!						
	: :						
	. ;				-10		
:				·			
					1		
i							-
:							

** This reference is being resubmitted in its entirety because when it was submitted in the original IDS dated April 15, 2002 part of a page was missing.

	OTHER DOCUMENTS (Include	ling Author, Title, Date, Pertinent Pages, Etc.) r / avadjasalsj. vi	Shiphopid A silve
(00.1	International Search Report			
				72.55.5
			7.7.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	ਵਿ _ਰ ਗੇ(15 ਨਥਾ) .
	1.77	· · · · · · · · · · · · · · · · · · ·	Halozy, of ol.,	"5-FT (1750) (
EXAMINE!	2 gelahar	DATE CONSIDERED, 132 GY		5-HT _{OK} End [©] Søm Niftespens⊢", 72:
	R: Initial if citation considered, whether or not cit		ray line through citation if not	

PTO/SB/08 (2-92) Patent and Trademark Office, U.S. Department of Commerce, a considered

<u>la conformacea and bot consiste serte tr</u>

PTO/SB/08 (2-92)

OIP	Eva
AUG 2 2	2002
T.	_6/

3

Form PTO-1449

INFORMATION DISCLOSURE CITATION BY APPLICANT

(Use several sheets if necessary)

	Sheet 1 ol 1
DOCKET NUMBER 100507 - 1	US APPLICATION NUMBER 10/051,776
APPLICANT AstraZeneca AB	110,001,110
FILING DATE January 16, 2002	GROUP ART UNIT

U.S. PATENT DOCUMENTS

lumber						Filing Date If Appropriate
	·	iomber	iomber	iomber	omber	ioniber

| Document Number | Public Date | Country | Chase | Subclass | Translation | Yes | No |

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
1,	Gaster, et al., "The Selective 5-HT1B Receptor Inverse Agonist 1'-Methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-					
1 50	oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289)					
l X~	Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo" J. Med. Chem., 41, 1218-					
9/	1235 (1998)					
Sign	Russell, et al., "3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT ₁₀ Receptor Agonists", <i>J. Med.</i>					
9/1	Chem., 42, 4981-5001, (1999)					
001	Barnes, et al., "A review of central 5-HT receptors and their function", Neuropharmacology 38, 1083-1152,					
V /	(1999)					
1001	Massot, et al., "5-HT1B Receptors: A Novel Target for Lithium", Neuropsychopharmacology Vol. 21, No. 4,					
<u> </u>	530-541					
S41	Halazy, et al., "5-HT _{18/1D} antagonists and depression", Exp. Opin. Ther. Patents, 7(4) 339352 (1997)					
100	Cryan et al., "5-HT _{1A} and Beyond: The Role of Serotonin and its Receptors in Depression and the					
8	Antidepressant Response", Hum. Psychopharmacol. Clin. Exp., 15, 113-135 (2000)					
EXAMINE	DATE CONSIDERED 4 32 04					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if no						
	In conformance and not considered. Include copy of this form with next communication to applicant.					
PTO/SB/08	(2-92) Patent and Trademark Office, U.S. Department of Commerce					